UCB SA (UCBJY)
67.62
+1.78
(+2.70%)
USD |
OTCM |
May 17, 16:00
UCB Enterprise Value: 27.68B for May 17, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 17, 2024 | 27.68B |
| May 16, 2024 | 27.00B |
| May 15, 2024 | 27.28B |
| May 14, 2024 | 26.72B |
| May 13, 2024 | 26.98B |
| May 10, 2024 | 27.12B |
| May 09, 2024 | 26.40B |
| May 08, 2024 | 26.70B |
| May 07, 2024 | 26.47B |
| May 06, 2024 | 26.49B |
| May 03, 2024 | 26.63B |
| May 02, 2024 | 26.90B |
| May 01, 2024 | 27.31B |
| April 30, 2024 | 27.15B |
| April 29, 2024 | 27.09B |
| April 26, 2024 | 27.24B |
| April 25, 2024 | 27.56B |
| April 24, 2024 | 26.60B |
| April 23, 2024 | 26.78B |
| April 22, 2024 | 26.66B |
| April 19, 2024 | 26.51B |
| April 18, 2024 | 26.18B |
| April 17, 2024 | 26.33B |
| April 16, 2024 | 26.04B |
| April 15, 2024 | 25.92B |
| Date | Value |
|---|---|
| April 12, 2024 | 26.26B |
| April 11, 2024 | 25.95B |
| April 10, 2024 | 25.52B |
| April 09, 2024 | 25.47B |
| April 08, 2024 | 25.60B |
| April 05, 2024 | 25.47B |
| April 04, 2024 | 25.64B |
| April 03, 2024 | 25.61B |
| April 02, 2024 | 25.43B |
| April 01, 2024 | 25.33B |
| March 28, 2024 | 25.40B |
| March 27, 2024 | 25.38B |
| March 26, 2024 | 25.50B |
| March 25, 2024 | 25.72B |
| March 22, 2024 | 25.46B |
| March 21, 2024 | 24.97B |
| March 20, 2024 | 24.34B |
| March 19, 2024 | 24.29B |
| March 18, 2024 | 24.11B |
| March 15, 2024 | 23.65B |
| March 14, 2024 | 24.03B |
| March 13, 2024 | 24.24B |
| March 12, 2024 | 24.45B |
| March 11, 2024 | 24.56B |
| March 08, 2024 | 24.79B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
11.93B
Minimum
Mar 18 2020
27.68B
Maximum
May 17 2024
19.26B
Average
18.99B
Median
Aug 28 2023
Enterprise Value Benchmarks
| Galapagos NV | -1.890B |
| Mithra Pharmaceuticals SA | -- |
| Nyxoah SA | 251.53M |
| Celyad Oncology SA | -- |
| MDxHealth SA | 100.52M |
Enterprise Value Related Metrics
| Earnings Yield | 1.42% |
| Operating Earnings Yield | 2.61% |
| Normalized Earnings Yield | 1.411 |